RJA
NGM

Raymond James & Associates’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Raymond James & Associates’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,714
Closed -$17.8K – 4072
2023
Q4 		$17.8K Sell
20,714
-1,209
-6% -$1.06K ﹤0.01% 3775
2023
Q3 		$23.5K Sell
21,923
-310
-1% -$642 ﹤0.01% 3722
2023
Q2 		$57.6K Sell
22,233
-6,343
-22% -$22.6K ﹤0.01% 3694
2023
Q1 		$117K Buy
28,576
+303
+1% +$1.4K ﹤0.01% 3616
2022
Q4 		$142K Sell
28,273
-67,413
-70% -$423K ﹤0.01% 3552
2022
Q3 		$1.25M Buy
95,686
+24,690
+35% +$374K ﹤0.01% 2259
2022
Q2 		$910K Buy
70,996
+8,108
+13% +$112K ﹤0.01% 2510
2022
Q1 		$959K Buy
+62,888
New +$981K ﹤0.01% 2625
2021
Q2 		– Sell
-80,692
Closed -$2.35M – 4244
2021
Q1 		$2.35M Buy
80,692
+18,817
+30% +$527K ﹤0.01% 1909
2020
Q4 		$1.88M Sell
61,875
-2,407
-4% -$52.7K ﹤0.01% 1924
2020
Q3 		$1.02M Buy
64,282
+6,388
+11% +$117K ﹤0.01% 2161
2020
Q2 		$1.14M Buy
+57,894
New +$1.11M ﹤0.01% 2070

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James & Associates's NGM Position: Q1 2024 in Review

Raymond James & Associates sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 20,714 shares — an estimated $17.8K sold.

Raymond James & Associates first reported a position in NGM in Q2 2020 and held it in 12 quarters. The position peaked at $2.35M in Q1 2021. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Raymond James & Associates reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 20,714 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $17.8K.
  • Raymond James & Associates first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Raymond James & Associates's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $2.35M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.